"studyTitle","studyAcronym","id","uuid:ID","versionIdentifier","rationale"
"Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","LZZT","StudyVersion_1","a98099d2-6515-460c-b8da-a1fd511cb78a","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
